Quarterly Education & Business Meeting! December 11, 2025. "Leqembi: Long-Term Treatment Choice for Early Alzheimer's Disease" - Sponsored by Eisai and Biogen

The program will begin promptly at 6:15pm followed by the GLC Business Meeting.

This program will:
Review the Prescribing Information for LEQEMBI® (lecanemab-irmb) for the treatment of MCI due to AD and mild AD dementia
and highlight key considerations for clinical practice, including:

• Identifying appropriate patients for treatment with LEQEMBI
• Key efficacy and safety data from the Clarity AD study
• Important Safety Information, including Boxed WARNING for ARIA
• Guidance for screening and management of ARIA
• Navigating the steps from diagnosis to treatment with LEQEMBI